OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of Greg Stanley as Vice President of Sales and Marketing for its global diagnostics business unit. Mr. Stanley brings to OPKO extensive experience and expertise in the market development and commercial operations of diagnostic products and services. Prior to joining OPKO, Mr. Stanley served as chief commercial officer of Oncimmune USA, LLC where he led the commercial strategy and market development for the company’s oncology platform in early cancer detection. Most notable was the successful launch and market growth of EarlyCDT®-Lung, the first commercially available blood test to aid in the early detection of lung cancer. Prior to this, Mr. Stanley served over 5 years as director of marketing and then national director of corporate accounts, for Roche Diagnostics where he led the successful market introduction of numerous diagnostic products in point of care, immunodiagnostics, hematology, clinical chemistry, blood gas, urinalysis and blood glucose. Mr. Stanley had increasing scope of responsibility in sales, marketing and management roles at Abbott Diagnostics, Chiron Corporation, and Radiometer prior to his time at Roche. He has been at the executive leadership level for over 15 years and during his tenure served on the board of directors for Radiometer and Oncimmune. Mr. Stanley received his B.S. degree, Business Administration, from the University of Missouri-St. Louis. “We are excited to have Greg joining the OPKO Diagnostics team here in Miami,” said David Okrongly, President of OPKO Diagnostics. “His experience at launching and gaining reimbursement for novel cancer diagnostic tests combined with his broad background in IVD sales and marketing is the perfect combination for the commercial leadership role in the OPKO Diagnostics business unit.” “We are fortunate to have Greg join the OPKO Diagnostics team where his commercial expertise will have a significant impact as we prepare for the launch of the 4Kscore™ prostate cancer diagnostic test and the Claros®1 in-office immunodiagnostic analyzer,” said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.